190 related articles for article (PubMed ID: 35038934)
1. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.
Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C
J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934
[TBL] [Abstract][Full Text] [Related]
2. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK; Neulinger MM; Stadler PC; Aoki R; French LE
J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
5. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
6. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
7. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
8. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.
Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z
Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.
Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM
R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618
[TBL] [Abstract][Full Text] [Related]
10. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
11. [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):639-644. PubMed ID: 31650946
[TBL] [Abstract][Full Text] [Related]
12. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
Lee O; Masood M; Nutan F
J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
[TBL] [Abstract][Full Text] [Related]
13. Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Antoon JW; Goldman JL; Lee B; Schwartz A
Pediatr Dermatol; 2018 Mar; 35(2):182-187. PubMed ID: 29315761
[TBL] [Abstract][Full Text] [Related]
14. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
Auquier-Dunant A; Mockenhaupt M; Naldi L; Correia O; Schröder W; Roujeau JC;
Arch Dermatol; 2002 Aug; 138(8):1019-24. PubMed ID: 12164739
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hasegawa A; Abe R
F1000Res; 2020; 9():. PubMed ID: 32595945
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
17. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.
Cao J; Li Q; Zhi X; Yang F; Zhu W; Zhou T; Hou X; Chen D
Transl Cancer Res; 2021 Aug; 10(8):3870-3876. PubMed ID: 35116686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
